Verona Pharma plc (I9SA F) stock market data APIs
€90.8494
-0.67(-0.7%)
as of October 6, 2025
Try our APIs with
free plan!
Verona Pharma plc Financial Data Overview
Price chart is built with
Anychart
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis Resources plc and changed its name to Verona Pharma plc in September 2006. The company was incorporated in 2005 and is based in London, the United Kingdom. As of October 7, 2025, Verona Pharma plc operates as a subsidiary of Merck Sharp & Dohme LLC.
Prev. Close
90.8494
Open
90.1778
High
90.8494
Low
89.9889
52 wk Range
31.6-92.2
Market Cap
12 134 M
Shares Outstanding
85 991 K
Revenue
222 M
Beta
0.052
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Verona Pharma plc data using free add-ons & libraries
Get Verona Pharma plc Fundamental Data
Verona Pharma plc Fundamental data includes:
- Net Revenue: 222 M
- EBITDA: -52 737 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-03
- EPS/Forecast: 0.16
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Verona Pharma plc News
New
Verona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to Suspend
Verona Pharma plc (NASDAQ:VRNA) is one of the 10 Best Non-Tech Stocks to Buy According to Reddit, supported by hedge fund interest.Verona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion ...
Merck Completes Acquisition of Verona Pharma
Acquisition strengthens Merck’s cardio-pulmonary portfolio with addition of Ohtuvayre® (ensifentrine), a first-in-class COPD maintenance treatment, that is expected to grow into the next decade RA...
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales
Verona Pharma plc LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, whic...
Assessing Verona Pharma (VRNA) Valuation After Recent Shareholder Returns and Business Momentum
Verona Pharma (NasdaqGM:VRNA) shares have delivered a strong performance over the past year, catching the attention of investors watching the biotech sector. The company’s recent momentum invites a ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
